Kadish A S, Romney S L, Ledwidge R, Tindle R, Fernando G J, Zee S Y, Van Ranst M A, Burk R D
Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461.
J Gen Virol. 1994 Sep;75 ( Pt 9):2277-84. doi: 10.1099/0022-1317-75-9-2277.
Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index > or = 5.0) to one or more E7 peptides were observed in 28.6% (12 of 42) of patients and 23.1% (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6% (seven of 11) showed a positive LP response compared with 14.3% (two of 14) of women infected with other HPV types (P = 0.02), 17.6% (three of 17) negative for HPV (P = 0.02) and 23.1% (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4% (five of 11) of patients infected with HPV -16, -31 or -33 compared with 7.1% (one of 14) patients infected with other HPVs (P = 0.04), 5.9% (one of 17) of women negative for HPV (P = 0.02) and 7.7% (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17-37, 37-54 and 62-80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72-97) was present in 7.7% (one of 13) of controls, 35.3% (six of 17) of HPV-negative patients, 42.9% (six of 14) of patients infected with other HPVs, and only 9.1% (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72-97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.
对42名因宫颈细胞学异常而前往阴道镜检查门诊的女性以及13名正常对照者进行了研究，以检测淋巴细胞增殖（LP）细胞介导免疫（CMI）反应以及对16型人乳头瘤病毒（HPV - 16）E7肽段的血清学反应性。通过对脱落的宫颈阴道细胞DNA进行Southern印迹杂交来确定HPV的类型。在42名患者中有28.6%（12/42）、13名对照者中有23.1%（3/13）观察到对一种或多种E7肽段的阳性LP反应（刺激指数≥5.0）。在感染HPV - 16、-31或-33的患者中，63.6%（7/11）表现出阳性LP反应，而感染其他HPV类型的女性中这一比例为14.3%（2/14）（P = 0.02），HPV检测阴性的女性中为17.6%（3/17）（P = 0.02），对照者（HPV状态未知）中为23.1%（3/13）（P = 0.05）。C末端肽段109（氨基酸72至97）在感染HPV - 16、-31或-33的患者中有45.4%（5/11）引发阳性LP反应，而感染其他HPV的患者中这一比例为7.1%（1/14）（P = 0.04），HPV检测阴性的女性中为5.9%（1/17）（P = 0.02），对照者中为7.7%（1/13）（P = 0.05）。还观察到针对E7肽段103、105和108（17 - 37、37 - 54和62 - 80）的HPV - 16组特异性LP反应，其差异具有临界显著性（P = 0.07）。对照者中有7.7%（1/13）、HPV阴性患者中有35.3%（6/17）、感染其他HPV的患者中有42.9%（6/14）以及感染HPV - 16、-31或-33的患者中仅有9.1%（1/11）对E7肽段109（72 - 97）有ELISA反应性（IgG）。因此，对C末端HPV - 16 E7肽段109（72 - 97）的CMI反应与HPV - 16及密切相关类型的持续性宫颈感染显著相关，而对E7肽段的血清学反应性并非HPV类型特异性的。
